Frozen chemistry controls bacterial infections
By sciencedaily.com
Chemists and molecular biologists have made an unexpected discovery in infection biology. The researchers can now show that two proteins that bind to one another slow down a chemical reaction central to the course of the disease in the bacteria Yersinia pseudotuberculosis. The results have been published in the Journal of Biological Chemistry.
"The discovery paves way for new insights in the regulation of bacterial virulence. The results have given us a new opportunity to study the pathogenic ability in bacteria," says Magnus Wolf-Watz, researcher at the Department of Chemistry at Umeå University, who led the study together with Hans Wolf-Watz, professor at the Department of Molecular Biology.
Yersinia pseudotuberculosis and many similar bacteria infect humans by injecting toxins, so-called effector proteins, through a needle-like organelle called injectisome. Previous research has already shown that the protein YscU plays an important part in the regulation of effector protein transportation. YscU is unique in its ability to cleave itself in two parts, as a consequence, one of these parts is then transported out through the injectisome.
By combining biological experiments with studies on atomic level, the research team discovered that another protein, YscP, binds to YscU and regulates its self-cleaving abilities. When the proteins bound to one another, the speed of the self-cleaving was greatly reduced.
"The chemical process behind the self-cleaving was cooled down by the interaction and was hence slowed down. The result is a good example of how biology and chemistry nearly always go hand in hand and is a huge step forward. This gives us new opportunities to study the regulation of the course of diseases," says Hans Wolf-Watz.
The studies on atomic level were conducted using magnetic resonance spectroscopy at the Department of Chemistry at the NMR for Life platform, which is a national infrastructure for NMR in Sweden.
"The initial investment to fund an NMR instrument that the Kempe Foundations facilitated paved way for further funding from both the Wallenberg Foundations and SciLifeLab. Also, the protein expertise platform in our labs was of crucial importance for undertaking the research project," says Magnus Wolf-Watz.
Source: https://www.sciencedaily.com/releases/2017/03/170303100420.htm
Sunday, May 31, 2026
Prochlorperazine: The Generic Form Of Compazine Explained
Prochlorperazine is the generic name of the medication sold under the brand name Compazine. Generic medications contain the same active ingredient at the same dose and strength as their brand name counterparts and must meet the same FDA standards for quality, purity, and bioequivalence. The development and approval of generic drugs play an important role in making effective treatments more accessible and affordable for patients. Nausea can significantly impair quality of life, especially when chronic. It interferes with adequate nutrition and hydration, leads to weight loss, and affects work and daily functioning. In cases of severe or persistent vomiting, dehydration and electrolyte imbalances are a risk and may require inpatient treatment. Managing underlying causes is essential for lasting relief, while antiemetics provide symptomatic control while underlying conditions are addressed or resolve on their own. The pharmacological action of prochlorperazine is the basis for its use in treating conditions within the category of nausea and vomiting relief. Understanding the mechanism by which the active compound produces its therapeutic effects helps patients appreciate why the medication needs to be taken consistently and at the correct dose to achieve the best results. Switching between brand name and generic versions of a medication is generally considered safe when the products are bioequivalent, but patients should inform their doctor if they notice any differences in effect after a formulary change. Some patients with conditions requiring precise drug levels in the blood may be monitored more closely during transitions. For most patients, however, approved generics provide equivalent therapeutic benefit to the brand name product. The https://mednewwsstoday.com/nausea/ section on nausea and vomiting relief covers both brand name and generic treatment options, giving patients a complete picture of what is available. Cost, insurance coverage, and pharmacy availability are practical factors to discuss with a pharmacist when filling a prescription for prochlorperazine.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.